– First-in-class checkpoint inhibitor IOS-1002 (concentrating on LILRB1 (ILT2), LILRB2 (ILT4), KIR3DL1) being evaluated as mono and mixture remedy in sufferers with superior strong tumors
Schlieren (Zurich Space), Switzerland – Could 24, 2023 – ImmunOs Therapeutics AG, a biopharmaceutical firm leveraging its HLA-based expertise platform to develop first-in-class therapeutics for the therapy of most cancers and autoimmune ailments, at this time introduced the initiation of dosing of sufferers in a Part 1 trial of its lead program IOS-1002 in Australia. IOS-1002 is a first-in-class checkpoint inhibitor concentrating on LILRB1 (ILT2), LILRB2 (ILT4), and KIR3DL1 for the therapy of superior strong tumors. As a multi-functional agent primarily based on a naturally occurring human leukocyte antigen (HLA) concentrating on a number of immune checkpoints, IOS-1002 is designed to activate each innate and adaptive immune cells and to set off profound anti-tumor exercise.
The continuing trial is predicted to enroll over 120 sufferers. The compound is being administered at a number of dose ranges to sufferers with superior strong tumors both as monotherapy or together with an anti-PD-1 monoclonal antibody. Main endpoints of the present Part 1a, first-in-human, open-label, non-randomized, multicenter research would be the security and tolerability of IOS-1002. Secondary endpoints embody efficacy, immunogenicity, pharmacokinetics, and pharmacodynamics of IOS-1002.
“IOS-1002 addresses sufferers with superior strong tumors which have restricted or no additional therapy choices,” stated IOS-1002 Part 1 Principal Investigator, Stephen Luen, M.D., of the Peter MacCallum Most cancers Centre, College of Melbourne. “Because the compound is designed to activate all the immune system and targets a number of immune checkpoints, we’re trying ahead to seeing additional medical information of this novel checkpoint inhibitor which can shut a big hole in present most cancers remedy.”
“We’re excited that our lead compound IOS-1002 has entered right into a first-in-human trial and that sufferers are being dosed,” stated Sean R. Smith, CEO of ImmunOs Therapeutics. “It is a crucial milestone on our journey to develop the following era of novel immunotherapies that may enhance the lives of sufferers with critical ailments.”
###
About ImmunOs Therapeutics AG
ImmunOs Therapeutics AG leverages its HLA-based expertise platform to develop first-in-class therapeutics for the therapy of most cancers and autoimmune ailments. The Firm has recognized particular HLA molecules recognized to activate the immune system and is using these HLA molecules because the spine of novel therapies able to stimulating each the innate and the adaptive immune programs of most cancers sufferers to remove tumor cells. ImmunOs’ lead program is a multi-functional fusion protein that blocks particular LILRB (leukocyte immunoglobulin-like) and KIR (killer cell immunoglobulin-like) receptors and prompts anti-tumor responses. ImmunOs can also be creating antibodies to dam the activation of particular HLA protein molecules related to autoimmune ailments.
The Firm is supported by main worldwide traders together with Samsara BioCapital, Lightspeed Enterprise Companions, Gimv, Pfizer Ventures, BioMed Companions, Schroder Adveq, Mission BioCapital, GL Capital, PEAK6, and Fiscus. ImmunOs is positioned in Schlieren, Switzerland, and Gaithersburg, MD, USA.
For extra data, please go to www.immunostherapeutics.com
Firm Contact
ImmunOs Therapeutics AG
Wagistrasse 14
8952 Schlieren (Zurich Space), Switzerland
data@immunostherapeutics.com
Media Inquiries
akampion
Dr. Ludger Wess / Ines-Regina Buth
Managing Companions
data@akampion.com
Tel. +49 40 88 16 59 64 /
Tel. +49 30 23 63 27 68
